gp iib การใช้

• Platelet aggregation is achieved by mediating expression of the glycoprotein complex GP IIb / IIIa in the cell membrane of platelets.
• In clinical trials, bivalirudin treated patients exhibited statistically significantly lower rates of bleeding than patients treated with heparin plus a GP IIb / IIIa inhibitor.
• *Differences in mortality favoring bivalirudin at 30 days and 6 months was maintained at 12 months and demonstrated a 24 % risk reduction in death compared to heparin plus GP IIb / IIIa inhibition.
• *Bivalirudin alone demonstrated no difference in the rates of composite ischemic complications ( death, MI, unplanned revascularization for ischemia ) versus heparin with GP IIb / IIIa inhibition ( 16.4 % vs 16.3 % ) at 12 months.
• *The incidence of net adverse clinical events ( 9.2 % vs . 10.0 % ) and major adverse cardiovascular events ( 7.6 % vs . 7.1 % ) was reduced by bivalirudin monotherapy versus unfractionated heparin ( UFH ) plus a GP IIb / IIIa inhibitor with significant reduction in rates of major bleeding ( 2.4 vs . 4.1 % ) at 30 days.